Use of clinical next‐generation sequencing to identify melanomas harboring SMARCB1 mutations

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0560|42|5|308-317

ISSN： 0303-6987

Source： JOURNAL OF CUTANEOUS PATHOLOGY, Vol.42, Iss.5, 2015-05, pp. : 308-317

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Consistent copy number changes and recurrent PRKAR1A mutations distinguish Melanotic Schwannomas from Melanomas: SNP‐array and next generation sequencing analysis

By  

GENES, CHROMOSOMES AND CANCER, Vol. 54, Iss. 8, 2015-08 ,pp. : 463-471

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of next‐generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 4, 2015-04 ,pp. : 643-650

John Wiley & Sons Inc

Access to resources Recommend Favorite

Next‐generation sequencing and the cytopathologist

By  

CANCER CYTOPATHOLOGY, Vol. 123, Iss. 2, 2015-02 ,pp. : 69-70

John Wiley & Sons Inc

Access to resources Recommend Favorite

Next-Generation Sequencing in the Analysis of Human Microbiota: Essential Considerations for Clinical Application

By Rogers Geraint B.   Bruce Kenneth D.  

Molecular Diagnosis & Therapy, Vol. 14, Iss. 6, 2010-12 ,pp. : 343-350

Adis International

Access to resources Recommend Favorite

Clinical trials for precision oncology using next-generation sequencing

By Simon Richard   Polley Eric  

Personalized Medicine, Vol. 10, Iss. 5, 2013-07 ,pp. : 485-495

Future Medicine

Access to resources Recommend Favorite